Could a chemo-immunotherapy combo tame hard-to-treat colorectal cancer?
NCT ID NCT05504252
First seen Jan 07, 2026 · Last updated Jun 11, 2026 · Updated 19 times
Summary
This study tests whether adding an immunotherapy drug (nivolumab) to a standard chemotherapy (Nordic FLOX) can help control or shrink metastatic colorectal cancer that is mismatch repair proficient (pMMR) or microsatellite stable (MSS). These types usually don't respond well to immunotherapy alone. The trial enrolls 80 adults with previously untreated, measurable metastatic disease. The goal is to see if the combination improves progression-free survival and may allow some patients to have surgery later.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Akershus University Hospital
Lørenskog, Akershus, 1478, Norway
-
Oslo University Hospital
Oslo, Akershus, 0424, Norway
-
St Olavs Hospital
Trondheim, Trøndelag, 7006, Norway
Conditions
Explore the condition pages connected to this study.